Literature DB >> 28515808

Clinical risk-stratification for prostate cancer: Where are we, and where do we need to go?

Matthew R Cooperberg1.   

Abstract

Entities:  

Year:  2017        PMID： 28515808      PMCID： PMC5434505          DOI： 10.5489/cuaj.4520

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  10 in total

1.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Authors:  Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-15       Impact factor: 7.038

2.  Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.

Authors:  Adam C Reese; Matthew R Cooperberg; Peter R Carroll
Journal:  J Urol       Date:  2010-05-15       Impact factor: 7.450

3.  Analysis of the Cancer of the Prostate Risk Assessment to predict for biochemical failure after external beam radiotherapy or prostate seed brachytherapy.

Authors:  Guila Delouya; Vimal Krishnan; Jean-Paul Bahary; Sandra Larrivée; Daniel Taussky
Journal:  Urology       Date:  2014-09       Impact factor: 2.649

4.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

5.  Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.

Authors:  Matthew R Cooperberg; Shiro Hinotsu; Mikio Namiki; Kazuto Ito; Jeanette Broering; Peter R Carroll; Hideyuki Akaza
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 6.  An updated catalog of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Pierre I Karakiewicz; Claus G Roehrborn; Michael W Kattan
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

7.  Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer.

Authors:  Michael W Kattan; Michael J Zelefsky; Patrick A Kupelian; Daniel Cho; Peter T Scardino; Zvi Fuks; Steven A Leibel
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

Review 8.  The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies.

Authors:  Jonathan S Brajtbord; Michael S Leapman; Matthew R Cooperberg
Journal:  Eur Urol       Date:  2016-09-08       Impact factor: 20.096

9.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

10.  The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.

Authors:  Vimal Krishnan; Guila Delouya; Jean-Paul Bahary; Sandra Larrivée; Daniel Taussky
Journal:  BJU Int       Date:  2014-03-14       Impact factor: 5.588
  10 in total
  2 in total

1.  Deep Neural Networks Outperform the CAPRA Score in Predicting Biochemical Recurrence After Prostatectomy.

Authors:  Paul Sargos; Nicolas Leduc; Nicolas Giraud; Giorgio Gandaglia; Mathieu Roumiguié; Guillaume Ploussard; Francois Rozet; Michel Soulié; Romain Mathieu; Pierre Mongiat Artus; Tamim Niazi; Vincent Vinh-Hung; Jean-Baptiste Beauval
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

2.  A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.

Authors:  Shivani Kamdar; Neil E Fleshner; Bharati Bapat
Journal:  BMC Cancer       Date:  2020-10-02       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.